2. Search Result
Search Result
Results for "

Anesthetized dogs

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17465
    Glycopyrrolate
    1 Publications Verification

    Glycopyrronium bromide; Glycopyrrolate bromide

    		 mAChR Cardiovascular Disease Neurological Disease Cancer
    Glycopyrrolate (Glycopyrronium bromide), a quaternary ammonium derivative, is a muscarinic receptor antagonist. Glycopyrrolate has bronchoprotective effect and produces a beneficial effect on blood pressure. Glycopyrrolate can be used for the research of bronchial diseases .
    Glycopyrrolate
  • HY-107063
    AHR-1911

    10-Undecen-1-yl-thiopseudourea iodide

    		 Histamine Receptor Cancer
    AHR-1911 (10-Undecen-1-yl-Thiopseudourea Iodide;Isothiuronium) is a thiourea-based anti-inflammatory and anti-tumor agent that has an improving effect on burned skin. AHR-1911 produces histamine-like effects when injected intradermally and may reduce arterial pressure in anesthetized dogs. AHR-1911 inhibits tumor growth and reduces microsomal and C-polysome protein synthesis .
    AHR-1911
  • HY-121460
    Spiraprilat

    		Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Spiraprilat is a potent angiotensin-converting enzyme (ACE) inhibitor. Spiraprilat has ability to improve left ventricular (LV) function and metabolism in anesthetized open-chest dogs with acute ventricular failure (ALVF) .
    Spiraprilat
  • HY-17465R
    Glycopyrrolate (Standard)

    		mAChR Neurological Disease Cancer
    Glycopyrrolate (Standard) is the analytical standard of Glycopyrrolate. This product is intended for research and analytical applications. Glycopyrrolate (Glycopyrronium bromide), a quaternary ammonium derivative, is a muscarinic receptor antagonist. Glycopyrrolate has bronchoprotective effect and produces a beneficial effect on blood pressure. Glycopyrrolate can be used for the research of bronchial diseases .
    Glycopyrrolate (Standard)
  • HY-105925
    Mefenidil

    MCN 2378

    		 Adrenergic Receptor Cardiovascular Disease
    Mefenidil (MCN 2378) is a selective cerebral vasodilator that is not affected by beta-adrenergic blockade. Mefenidil can be used in the study of cardiovascular disease. In monkey models, mefenidil preferentially increases cerebral blood flow over systemic (femoral) blood flow. Mefenidil is also able to reduce systemic arterial pressure in anesthetized dogs.
    Mefenidil
  • HY-129445
    SG-209

    		Potassium Channel Cardiovascular Disease
    SG-209 is a Nicorandil (HY-B0341) derivative that produces relaxation through potassium channel activation, while this action contributes to the vasodilating action of Nicorandil (HY-B0341) at higher concentrations. SG-209 dilates tracheal smooth muscle and increases tracheal blood flow in anesthetized dogs .
    SG-209
  • HY-118233
    Alilusem potassium

    M 17055

    		 Chloride Channel Neurological Disease
    Alilusem potassium is a diuretic. In anesthetized dogs undergoing water diuresis, Alilusem potassium effectively decreased free water clearance and increased Na+ and Cl- levels in excreted urine. When combined with Furosemide (HY-B0135) or Hydrochlorothiazid, Alilusem potassium further inhibited free water clearance. Alilusem potassium inhibited the lumen-positive transepithelial voltage and lumen-to-cistern Cl- flux in isolated rabbit cortical thick ascending limbs of Henle .
    Alilusem potassium
  • HY-121670
    Ambenoxan

    		Others Neurological Disease
    Ambenoxan is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.
    Ambenoxan
  • HY-121670A
    Ambenoxan hydrochloride

    		Others Neurological Disease
    Ambenoxan hydrochloride is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.
    Ambenoxan hydrochloride
  • HY-167848
    DMP-728 free base

    XL-118

    		 Others Cardiovascular Disease
    DMP-728 free base (XL-118) is a highly potent and selective GPIIb/IIIa antagonist with antiplatelet and antithrombotic activities. DMP-728 free base can inhibit ADP-induced human platelet aggregation in vitro, with an IC50 of 46 nmol/L, and can significantly reduce the interaction between fibrinogen and human platelets or Binding of purified human GPIIb/IIIa receptors. DMP-728 free base exhibits dose-dependent antiplatelet effects in anesthetized mongrel dogs, effectively inhibiting ADP-induced platelet aggregation and prolonging template bleeding time .
    DMP-728 free base
  • HY-137055
    PF-3774076

    		Others Others
    PF-3774076 is a highly central nervous system (CNS) penetrant, potent, and selective human α1A-adrenoceptor partial agonist. It exhibits good potency and selectivity in multiple binding and functional assays. PF-3774076 increases peak urethral pressure in anesthetized female dogs in a dose-dependent manner via a central mechanism. PF-3774076 affects both the proximal and distal portions of the urethra in vivo. These properties suggest that PF-3774076 may have significant benefit in the treatment of stress urinary incontinence (SUI) as a CNS-penetrant α1A receptor partial agonist. However, despite its partial agonism and selectivity for α1A receptors, PF-3774076 failed to provide adequate safety differences in in vivo models of cardiovascular function. This may be due to the simultaneous activation of both peripheral and central α1A receptors. These data suggest that while central α1A partial agonists may have significant benefit in the treatment of SUI, this class of agents may have difficulty achieving the desired urethral selectivity without affecting cardiovascular function.
    PF-3774076

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: